← Product Code [NBW](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/NBW) · K091815

# SUPERCHECK 1 BLOOD GLUCOSE MONITORING SYSTEM, MODEL 6268 (K091815)

_Biotest Medical Corp. · NBW · Nov 16, 2009 · Clinical Chemistry · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/NBW/K091815

## Device Facts

- **Applicant:** Biotest Medical Corp.
- **Product Code:** [NBW](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/NBW.md)
- **Decision Date:** Nov 16, 2009
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 862.1345
- **Device Class:** Class 2
- **Review Panel:** Clinical Chemistry
- **Attributes:** Pediatric

## Indications for Use

The SuperCheck 1 Blood Glucose Monitoring System, Model 6268, is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the forearm. It is intended for use by healthcare professionals and people with diabetes mellitus at home and as an aid in monitoring the effectiveness of a diabetes control program. The SuperCheck 1 Blood Glucose Monitoring System is not intended for the diagnosis of or screening for diabetes mellitus, nor for use with neonates. The alternative site testing (forearm) in this system can only be used during steady-state blood glucose conditions. This system contains a speaking function that provides audible test results for users with low vision.

## Device Story

System measures glucose in capillary whole blood via glucose oxidase amperometry; requires 0.7 uL sample; 6-second reaction time. Meter includes speaking function for visually impaired users; RS232 port for data transfer. Used by patients at home or healthcare professionals in clinical settings. Input: blood sample on test strip; Output: quantitative glucose concentration displayed on LCD and provided via audible voice output. Benefits: enables self-monitoring of blood glucose levels for diabetes management. Device uses thermistor for automatic temperature compensation. No coding required; meter and strip reference numbers must match.

## Clinical Evidence

Performance evaluated via laboratory and clinical studies involving both healthcare professionals and lay users. Studies confirmed system performance meets intended use criteria. No specific sensitivity/specificity metrics provided in summary.

## Technological Characteristics

Electrochemical glucose monitoring system. Includes speaking function for audible results. Supports alternate site testing (forearm).

## Regulatory Identification

A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

## Special Controls

*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

## Predicate Devices

- Prodigy Voice Blood Glucose Monitoring System (k073118)

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

A. 510(k) Number:
k091815

B. Purpose for Submission:
New device

C. Measurand:
Whole blood glucose

D. Type of Test:
Quantitative, glucose oxidase

E. Applicant:
Biotest Medical Corporation

F. Proprietary and Established Names:
SuperCheck 1 Blood Glucose Monitoring System

G. Regulatory Information:
1. Regulation section:
21 CFR 862.1345 Glucose Test System
2. Classification:
Class II
3. Product code:
NBW - Blood glucose test system, over the counter
CGA - Glucose oxidase, glucose test system

{1}

4. Panel:
Clinical Chemistry

H. Intended Use:

1. Intended use(s):
Refer to indications for use below.

2. Indication(s) for use:
The SuperCheck 1 Blood Glucose Monitoring System, Model 6268, is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the forearm. It is intended for use by healthcare professionals and people with diabetes mellitus at home and as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis or screening for diabetes mellitus, and is not for use with neonates.

The alternative site testing (forearm) in this system can only be used during steady-state blood glucose conditions.

This system contains a speaking function that provides audible test results for users with low vision.

3. Special conditions for use statement(s):
It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. For in vitro diagnostic use only, over-the-counter use, and prescription use. The device should not be used for patients who are dehydrated, in shock, critically ill, or experiencing a hyperglycemic-hypersmolar state.

4. Special instrument requirements:
Biotest Medical Corp., SuperCheck 1 Blood Glucose Monitoring System

I. Device Description:
The SuperCheck 1 Blood Glucose Monitoring System, Model 6268, consists of a blood glucose meter, blood glucose test strips, control solutions, the lancing device, and lancets. The system is available either as a meter alone or as a kit. The control solutions were previously cleared under k032029. The meter comes with a speaking function that provides audible test results for users with low vision. The SuperCheck 1 Model 6268 allows the forearm to be used as an alternative site.

J. Substantial Equivalence Information:

{2}

1. Predicate device name(s):

Prodigy Voice Blood Glucose Monitoring System

2. Predicate 510(k) number(s):

k073118

3. Comparison with predicate:

|  Comparison Table  |   |   |
| --- | --- | --- |
|  Item | Device (k091815) | Predicate (k073118)  |
|  Indications for Use | The SuperCheck 1 Blood Glucose Monitoring System, Model 6268, is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the forearm. It is intended for use by healthcare professionals and people with diabetes mellitus at home and as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, not for use with neonates. The alternative site testing (forearm) in this system can only be used during steady-state blood glucose conditions. This system contains a speaking function that provides audible test results for users with low vision. | The Prodigy Voice Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the following alternative sites: the palm, the forearm, the upper-arm, the calf, and the thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus. The alternative site testing in this system can be used only during steady-state blood glucose conditions. This system contains a speaking functionality which provides step by step instructions to aid visually impaired persons.  |
|  Detection method | Amperometry | same  |
|  Enzyme | Glucose Oxidase (Aspergillus niger) | same  |
|  Temperature compensation | Automatic compensation with built-in thermister | same  |

{3}

|  Comparison Table  |   |   |
| --- | --- | --- |
|  Item | Device (k091815) | Predicate (k073118)  |
|  Sample volume | 0.7 uL | same  |
|  Reaction time | 6 seconds | 7 seconds  |
|  Measurement range | 20-600 mg/dL | same  |
|  Meter dimensions | 99(L) x 62(W) x 29(H) | 95(L) x 55(W) x 18(H)  |
|  Meter weight | 90 g | 75 g  |
|  Operating conditions | 10°C - 40°C, 20-80% R.H. | 10°C - 40°C, Below 85% R.H.  |
|  Strip calibration | No coding. The meter and test strip have the same reference number printed on the meter box and on the test strip box and vial. | One code for all lots, with the user checking that the code number that appears on the meter display and on the test strip vial is correct.  |
|  Memory feature | 500 measurements with day and time | 450 measurements with day and time  |
|  Day average | 7-, 14-, 28-, 60-, 90-day average glucose result | 7-, 14-, 21-, 28-, 60-, 90-day average glucose result  |
|  Auto Shut Off | 2 minutes | 3 minutes  |
|  Alarm | Beeping sound and/or error message in LCD display | same  |
|  Communication | RS232 port | same  |
|  Speaking function | Yes | same  |
|  Strip vial open-vial stability | 3-months | same  |

K. Standard/Guidance Document Referenced (if applicable):

1. ISO 13640:2002. Stability Testing of In Vitro Diagnostic Reagents. (In Vitro Diagnostics).
2. EN 552:1994. Sterilization of medical devices. Validation and routine control of sterilization by irradiation.
3. EN 61326-1:2006. Electrical equipment for measurement, control, and laboratory use. EMC Requirements. General requirements.
4. ISO 10993-5:1999. Biological evaluation of medical devices, Part 5: Tests for in vitro cytotoxicity.
5. ISO 10993-10:2002. Biological evaluation of medical devices, Part 10: Tests for irritation and delayed-type hypersensitivity.
6. ISO 11137-1:1995. Sterilization of health care products. Requirements for validation and routine control of a sterilization process for medical devices.
7. ISO 14971:2007. Medical devices-Application of risk management to medical devices.
8. ISO 15197. In vitro diagnostic test systems. Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus.
9. EN 60601-1-1. Medical electrical equipment, Part 1-1. General requirements for safety. Safety requirements for medical electrical systems.

{4}

10. EN 60601-1-2:2001 (A1:2006). Medical electrical equipment, Part 1-2. General requirements for basic safety and essential performance. Electromagnetic Compatibility.
11. EN 60601-1:1988 (A1:1991, A2:1995). Medical electrical equipment, Part 1. General requirements for safety.
12. EN 61010-1:2001. Safety requirements for electrical equipment for measurement, control, and laboratory use, Part 1. General requirements.
13. IEC/EN 61010-2-101:2002. Safety requirements for electrical equipment for measurement, control, and laboratory use, Part 2-101. Particular requirements for in vitro diagnostic (IVD) medical equipment.

## L. Test Principle:

The test is based on the measurement of electrical current generated by the reaction of glucose with the reagent of the strip. The meter measures the current and displays the corresponding blood glucose level. The strength of the current produced by the reaction depends on the amount of glucose in the blood sample.

## M. Performance Characteristics (if/when applicable):

### 1. Analytical performance:

#### a. Precision/Reproducibility:

Precision studies to determine repeatability and intermediate precision were based on ISO 15197 standard. A repeatability study was conducted using blood samples at five different levels of glucose ranging from 49 to 391 mg/dL on three different reagent system lots, four packages per lot. Ten replicate measurements were obtained for each concentration and for each of twelve meters. An intermediate precision study was conducted using control material at three different glucose levels ranging from 46 to 366 mg/dL on three different reagent system lots, four packages per lot.

Measurements were obtained for each concentration and for each of twelve meters for a period of ten days. The mean, standard deviation (SD), and coefficients of variation (CV) were determined for each sample, see results below:

|  Repeatability Data Summary  |   |   |   |   |   |
| --- | --- | --- | --- | --- | --- |
|  Sample | 1 | 2 | 3 | 4 | 5  |
|  Grand Mean (mg/dL) | 49 | 90 | 128 | 246 | 391  |
|  Pooled SD (mg/dL) | 0.64 | 0.79 | 1.02 | 1.63 | 3.12  |
|  Pooled CV | 1.31% | 0.88% | 0.80% | 0.66% | 0.80%  |
|  Intermediate Precision Data Summary  |   |   |   |
| --- | --- | --- | --- |
|  Sample | 1 | 2 | 3  |
|  Grand Mean (mg/dL) | 43 | 123 | 366  |
|  Pooled SD (mg/dL) | 0.65 | 1.28 | 3.51  |

{5}

|  Pooled CV | 1.41% | 1.04% | 0.96%  |
| --- | --- | --- | --- |

# b. Linearity/assay reportable range:

A linearity study based on CLSI EP6-A standard was conducted on whole blood samples at twelve different glucose levels ranging from 20 to  $605\mathrm{mg / dL}$ . Duplicate measurements for each glucose level were conducted on each of ten meters, three strip lots, and 10 vials per strip lot. Regression analysis showed a linear relationship between the SuperCheck 1 glucose monitoring system and the YSI-2300 reference method. The linear regression was as follows:  $\mathrm{Y} = 1.0034\mathrm{X} + 7.958$ ,  $\mathrm{r}^2 = 0.9981$ ,  $\mathrm{n} = 360$ . The reportable range of the SuperCheck 1 glucose monitoring system was confirmed to be 20 to  $600\mathrm{mg / dL}$ . If a sample is less than  $20\mathrm{mg / dL}$ , the result is flagged by the meter as LO. If a sample result exceeds  $600\mathrm{mg / dL}$ , the result is flagged by the meter as HI.

# c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The stability of the SuperCheck 1 test strips was demonstrated by real-time stability studies. The unopened shelf life is 11 months and the open-vial stability is 3 months at the recommended storage temperatures of  $8^{\circ}\mathrm{C}$  to  $30^{\circ}\mathrm{C}$ .

Value assignment for use of the control solutions with the SuperCheck1 test strips is based on measurements using the YSI-2300 reference method after calibration with YSI 2747 calibrator solution (NIST SRM #917A Clinical Dextrose). The control solutions were previously cleared under k032029.

The acceptable ranges are printed on the test strip vial labels.

# d. Detection limit:

The measuring range of the SuperCheck 1 glucose monitoring system is 20 to 600 mg/dL. This range was verified by the linearity study (see section M.1.b of this decision summary).

# e. Analytical specificity:

Interferences Study: A study was performed based on the CLSI EP7-A standard to test for possible interference due to a number of endogenous and exogenous substances. Control samples spiked at glucose levels of 80 and  $120\mathrm{mg / dL}$  were tested in five replicates with the SuperCheck 1 glucose monitoring system and in singlicate with the YSI-2300 reference method. Each potential interfering substance was evaluated using samples containing a low  $(80\mathrm{mg / dL})$  and a high  $(120\mathrm{mg / dL})$  glucose level and compared against a control pool after measurements on the SuperCheck 1 glucose monitoring system and the YSI-2300 reference method. The table below shows the levels with no interference when testing for glucose with the SuperCheck 1 glucose monitoring system:

{6}

|  Substance | Reference/Therapeutic Level | No Interference at Listed Level  |
| --- | --- | --- |
|  Endogenous Substance |   |   |
|  Bilirubin | 0.29~1.23 mg/dL | 20.8 mg/dL  |
|  Cholesterol | 114.2~201.2 mg/dL | 483.8 mg/dL  |
|  Creatinine | 0.6~1.3 mg/dL | 6.3 mg/dL  |
|  Hemoglobin | 100~200 mg/dL | 500 mg/dL  |
|  Triglycerides | 10.3~111.7 mg/dL | 1183.8 mg/dL  |
|  Uric Acid | 2.5~8.0 mg/dL | 10.9 mg/dL  |
|  Exogenous Substance |   |   |
|  Acetaminophen | 1~3 mg/dL | 6.2 mg/dL  |
|  Ascorbic Acid | 0.4~2.0 mg/dL | 4.5 mg/dL  |
|  Caffeine | 0.5~2.0 mg/dL | 6 mg/dL  |
|  Dopamine | 0.03 mg/dL | 0.09 mg/dL  |
|  Ephedrine HCl | 1 mg/dL | 3.6 mg/dL  |
|  Ibuprofen | 1~7 mg/dL | 37.5 mg/dL  |
|  L-Dopa | 5 mg/dL | 1.9 mg/dL  |
|  Methyl-Dopa | 0.10~0.75 mg/dL | 1.5 mg/dL  |
|  Salicylate | 36 mg/dL | 115.5 mg/dL  |
|  Tetracycline | 0.2~0.5 mg/dL | 1.5 mg/dL  |
|  Tolbutamide | 5.4~10.8 mg/dL | 64 mg/dL  |
|  Anticoagulants |   |   |
|  EDTA | 400 mg/dL | 800 mg/dL  |
|  Heparin | 4000 U/dL | 8000 U/dL  |

The sponsor included the following limitation in the label:

Interference was observed for therapeutic level of L-Dopa. Uric acid, acetaminophen, ascorbic acid, and ibuprofen have no significant interference in normal therapeutic levels. However, the concentration in blood beyond the following levels may cause inaccurate results: uric acid (10.9 mg/dL), acetaminophen (6.2 mg/dL), ascorbic acid (4.5 mg/dL), and ibuprofen (37.5 mg/dL).

Hematocrit Study: A study was performed to evaluate the blood hematocrit (HCT) effect on the performance of the SuperCheck 1 glucose monitoring system across the measuring range of the assay. Whole blood samples were tested in duplicate with the SuperCheck 1 glucose monitoring system using three lots of strips/twelve vials per lot and eighteen meters. Glucose concentrations at each HCT level (30%, 32%, 35%, 40%, 46%, 50%, 56%, and 60%) were compared with results obtained with the YSI-2300 reference method. The data were within ± 10 mg/dL for glucose levels < 75 mg/dL and within ± 15% for glucose levels ≥ 75 mg/dL for the claimed HCT range. The sponsor included the following limitation in the label: Hematocrit in the range of 32-56% has been shown not to affect the glucose results. If you do not know your hematocrit level, consult with your healthcare professional.

{7}

Altitude Study: The effect of altitude was evaluated by testing whole blood samples at 120 and 240 mg/dL on the SuperCheck 1 glucose monitoring system using three lots of strips/ten vials per lot and ten meters. Glucose concentrations at different altitude levels were compared with results obtained with the Hemocue Glucose Analyzer reference method. The measurements were acceptable when compared to the reference method results. The sponsor included the following limitation in the label: The test strips may be used at altitudes up to 5,280 feet without an effect on test results.

Humidity Study: The effect of humidity on the performance of the SuperCheck 1 glucose monitoring system was evaluated at three glucose levels (Low-76.5-79.4 mg/dL; Medium-136-144 mg/dL; and High-329-338 mg/dL) using whole blood samples. Ten replicates were tested at each glucose level with the SuperCheck 1 glucose monitoring system using three lots of strip/ten vials per lot and ten meters. Glucose concentrations at each humidity level (20%, 40%, 60%, 80%, and 95% R.H.) were compared with results obtained with the YSI-2300 reference method. The study results demonstrated that humidity between 20% R.H. and 95% R.H. did not affect glucose measurements. Results fell within ± 7%.

Temperature Study: A study was performed to evaluate the effect of temperature on the performance of the SuperCheck 1 glucose monitoring at three glucose levels (Low-77.8-79 mg/dL; Medium-137-142 mg/dL; and High-325-335 mg/dL) using whole blood samples. Ten replicates were tested at each glucose level with the SuperCheck 1 glucose monitoring system using three lots of strip/ten vials per lot and ten meters. Glucose concentrations at each temperature level (10, 20, 30, and 40°C) were compared with results obtained with the YSI-2300 reference method. The study results demonstrated that temperatures between 10°C and 40°C did not affect glucose measurements. Results fell within ± 7%.

f. Assay cut-off:

Not applicable

2. Comparison studies:

a. Method comparison with predicate device:

Comparison studies were performed with the YSI-2300 reference method. System accuracy, lay-user performance evaluation, and a visually impaired user study were performed. Results were subjected to acceptance criteria described in the ISO 15197 standard.

System Accuracy: In the method comparison study, samples from the finger and forearm of 159 subjects were used for blood glucose measurements by healthcare professionals. From these, 26 capillary whole blood samples were adjusted to achieve the extreme low and high glucose concentrations recommended in the ISO 15197

{8}

standard. Measurements obtained with the SuperCheck 1 glucose monitoring system were compared to those obtained with the YSI-2300 reference method. The study was performed with three SuperCheck 1 glucose monitoring systems. The accuracy data is summarized in tables below.

|  Accuracy Study Regression Statistics | Finger | Forearm  |
| --- | --- | --- |
|  Number of samples (n) | 159 | 159  |
|  Range of YSI Glucose Values (mg/dL) | 25-500 | 25-500  |
|  Slope | 1.0254 | 1.0094  |
|  Intercept | -0.5618 | 2.3951  |
|  Correlation coefficient | 0.9972 | 0.9954  |
|  R square | 0.9945 | 0.9908  |
|  Accuracy Study Results  |   |   |   |   |
| --- | --- | --- | --- | --- |
|  Glucose < 75 mg/dL  |   |   |   |   |
|   | Within ± 5 mg/dL | Within ±10 mg/dL |   | Within ± 15 mg/dL  |
|  Finger Sample | 10/19 (53%) | 17/19 (89%) |   | 19/19 (100%)  |
|  Forearm Sample | 12/19 (63%) | 19/19 (100%) |   | 19/19 (100%)  |
|  |   |   |   |   |
|  Glucose ≥ 75 mg/dL  |   |   |   |   |
|   | Within ± 5 % | Within ±10 % | Within ± 15 %  |   |
|  Finger Sample | 98/140 (70%) | 130/140 (93%) | 138/140 (99%)  |   |
|  Forearm Sample | 72/140 (51%) | 120/140 (86%) | 135/140 (96%)  |   |
|  |   |   |   |   |

Lay-user Study: In the user performance study, 134 subjects were used for blood glucose measurements from the finger and the forearm. Subjects were provided with instructions for use and tested their own capillary whole blood samples from both the finger and forearm using the SuperCheck 1 glucose monitoring system. Healthcare professionals then tested these samples using the SuperCheck 1 glucose monitoring system and the YSI-2300 reference method. The study was performed with three SuperCheck 1 glucose monitoring systems. The accuracy data is summarized in tables below.

|  Lay-user Study Regression Statistics  |   |   |
| --- | --- | --- |
|  Finger | User vs. Reference | User vs. Professional  |
|  Number of samples (n) | 134 | 134  |
|  Range of YSI Glucose Values (mg/dL) | 63-490 | 63-490  |
|  Slope | 1.0685 | 1.0306  |
|  Intercept | -1.6786 | -0.2492  |
|  Correlation coefficient | 0.9902 | 0.9906  |
|  R square | 0.9806 | 0.9813  |
|  Forearm | User vs. Reference | User vs. Professional  |

{9}

|  Number of samples (n) | 134 | 134  |
| --- | --- | --- |
|  Range of YSI Glucose Values (mg/dL) | 63-490 | 63-490  |
|  Slope | 1.0321 | 1.0226  |
|  Intercept | 2.5219 | -0.7381  |
|  Correlation coefficient | 0.9869 | 0.9910  |
|  R square | 0.974 | 0.982  |
|  Lay-user Study Results  |   |   |   |   |
| --- | --- | --- | --- | --- |
|  Glucose < 75 mg/dL  |   |   |   |   |
|  Finger Sample | Within ± 5 mg/dL | Within ±10 mg/dL | Within ± 15 mg/dL  |   |
|  Patient (vs. YSI) | 2/8 (25%) | 7/8 (88%) | 8/8 (100%)  |   |
|  Professional (vs. YSI) | 5/8 (63%) | 8/8 (100%) | 8/8 (100%)  |   |
|  |   |   |   |   |
|  Forearm Sample | Within ± 5 mg/dL | Within ±10 mg/dL | Within ± 15 mg/dL  |   |
|  Patient (vs. YSI) | 1/8 (13%) | 4/8 (50%) | 8/8 (100%)  |   |
|  Professional (vs. YSI) | 6/8 (75%) | 8/8 (100%) | 8/8 (100%)  |   |
|  |   |   |   |   |
|  Glucose ≥ 75 mg/dL  |   |   |   |   |
|  Finger Sample | Within ± 5 % | Within ±10 % | Within ± 15 % | Within ± 20%  |
|  Patient (vs. YSI) | 40/126 (32%) | 87/126 (69%) | 112/126(89%) | 123/126 (98%)  |
|  Professional (vs. YSI) | 93/126 (74%) | 116/126 (92%) | 124/126 (98%) | 126/126 (100%)  |
|  |   |   |   |   |
|  Forearm Sample | Within ± 5 % | Within ±10 % | Within ± 15 % | Within ± 20%  |
|  Patient (vs. YSI) | 39/126 (31%) | 77/126 (61%) | 105/126 (83%) | 120/126 (95%)  |
|  Professional (vs. YSI) | 63/126 (50%) | 107/126 (85%) | 121/126 (96%) | 126/126 (100%)  |

Visually Impaired User Study: Fifty subjects with visual impairment were enrolled and user performance testing was performed using the SuperCheck 1 glucose monitoring system and the YSI-2300 reference method. The subjects in this test included those with vision category from 1 to 5, diagnosed per WHO Guidelines as ICD Version 2007. User performance was evaluated with subjects using the device with audible English language instructions. Subjects tested themselves on one meter and then were tested by healthcare professionals. Usability of the device was evaluated by users with a questionnaire.

|  Visually Impaired User Study Regression Statistics | User vs. Reference | User vs. Professional  |
| --- | --- | --- |
|  Number of samples (n) | 50 | 50  |
|  Range of YSI Glucose Values (mg/dL) | 64-342 | 64-342  |
|  Slope | 1.0623 | 1.0161  |
|  Intercept | -5.2254 | -1.5977  |
|  Correlation coefficient | 0.9899 | 0.9971  |
|  R square | 0.9799 | 0.9942  |

{10}

|  Visually Impaired User Study Results  |   |   |   |   |
| --- | --- | --- | --- | --- |
|  Glucose < 75 mg/dL  |   |   |   |   |
|   | Within ± 5 mg/dL | Within ±10 mg/dL | Within ± 15 mg/dL  |   |
|  User (vs. YSI) | 1/4 (25%) | 3/4 (75%) | 4/4 (100%)  |   |
|  |   |   |   |   |
|  Glucose ≥ 75 mg/dL  |   |   |   |   |
|   | Within ± 5 % | Within ±10 % | Within ± 15 % | Within ± 20%  |
|  User (vs. YSI) | 24/46 (52%) | 37/46 (80%) | 44/46 (96%) | 46/46 (100%)  |

b. Matrix comparison:

Not applicable

3. Clinical studies:

a. Clinical Sensitivity:

Not applicable

b. Clinical specificity:

Not applicable

c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable

4. Clinical cut-off:

Not applicable

5. Expected values/Reference range:

Expected plasma blood glucose values for normal, nondiabetic adults are as follows:

Before eating  &lt; 100 mg/dL

Two hours after meals  &lt; 140 mg/dL

Reference: American Diabetes Association: Diabetes Care, January 2007, volume 30 (suppl. 1) S42-S47.

N. Instrument Name:

Biotest Medical Corp., SuperCheck 1 Blood Glucose Meter

{11}

O. System Descriptions:

1. Modes of Operation:

Each test strip is single use and must be replaced with a new strip for additional readings. The labeling and user guide specify the lancet and the strip are for single use only and instruct the user to discard immediately after use.

Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?:
Yes ☐ X or No ☐

Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?:
Yes ☐ or No ☐ X

2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:
Yes ☐ X or No ☐

3. Specimen Identification:

There is no sample identification function with this device. Samples are applied directly to the test strip as they are collected.

4. Specimen Sampling and Handling:

This device is intended to be used with capillary whole blood from the finger and the forearm (AST) which can be applied directly to the test strip.

5. Calibration:

No coding. The meter and test strip have the same reference number printed on the meter box and on the test strip box and vial.

6. Quality Control:

The sponsor provides one level of control (Medium) with this glucose monitoring system. Two additional controls (Low and High) are available when requested by the customer using the contact information provided in the User Manual. When the test strip is inserted into the meter, each control can be measured by following the instructions for “Running a Control Solution Test” provided in the User Manual for the meter. An acceptable range for each control level is printed on the test strip vial label. The user is instructed to

{12}

contact a customer assistance line during operational hours or a healthcare provider outside hours of operation if the control results fall outside these ranges. Controls values and value ranges are assigned as described in section M.1.c of this decision summary.

P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:

Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

---

**Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/NBW/K091815](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/NBW/K091815)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com